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A B S T R A C T
This case reports cryptococcal meningitis in an HIV positive woman on antiretroviral therapy, presenting with
left middle cerebral artery stroke at 30 weeks gestation. The patient had well-controlled HIV (CD4 count over
200 cells/mL). The immunosuppressive eﬀects of the pregnancy likely contributed to the development of
cryptococcal disease. The patient was successfully treated with two weeks of amphotericin B followed by ﬂu-
conazole, delivered a healthy baby, but remained with a permanent severe neurological deﬁcit.
1. Introduction
This case reports the diﬃculties in treating pregnant patients di-
agnosed with cryptococcal meningitis. Cryptococcal meningitis is a
common disease in sub-Saharan Africa and is estimated to cause more
than 100,000 deaths annually in the developing world [1,2], with
mortality rates up to 68% [3]. It usually presents with a gradually
progressive headache, and commonly results in cranial nerve defects
and seizures. Worldwide cryptococcal meningitis is a disease occurring
predominantly in those with T-cell immunosuppression secondary to
HIV infection, and is an AIDS deﬁning illness. We present a case here of
a pregnant patient with an unusual presentation of cryptococcal me-
ningitis.
2. Case
A 34-year-old female HIV-positive pregnant patient presented at 30
weeks gestation with collapse after feeling dizzy, with subsequent
aphasia. There were no witnessed seizures, and she had not reported
headache prior to collapse. The patient's HIV had been diagnosed 3
years prior, and she had been started at this time on antiretroviral
therapy consisting of tenofovir, lamivudine and efavirenz, and co-tri-
moxazole prophylaxis, with excellent adherence evidenced by family
report and medical records. There was no history of hypertension,
diabetes, epilepsy, tuberculosis, or previous cryptococcal infection.
On examination, she had a fever of 38.2 °C, reduced movement of
the right arm and leg, and a right-sided 7th cranial nerve palsy.
Modiﬁed Rankin score 5/6. Glasgow coma score 10/15. Cardiovascular,
respiratory, abdominal and fundoscopic examinations were unremark-
able.
The patient was therefore diagnosed clinically with a left middle
cerebral artery stroke. Diﬀerential diagnoses included infections such as
toxoplasmosis, tuberculosis, cryptococcal meningitis, cerebral bacterial
abscess, neurosyphilis, viral encephalitis, HIV encephalopathy, pro-
gressive multifocal leukoencephalopathy and cerebral malaria. Non-
infective diﬀerentials included thromboembolic stroke, primary cere-
bral lymphoma, primary brain cancer or metastatic brain cancer.
Cerebrospinal ﬂuid (CSF) from day 0 was positive for cryptococcus
on India ink microscopy and cryptococcal antigen test (CrAg). Lumbar
puncture was repeated on day +2 when the CrAg and India ink re-
mained positive. The opening pressure on day +2 was 25 cm (normal
range<20 cm), white cell count 2 cells/µL (normal range 0–5 cells/
µL), glucose 1.1 mmol/L (normal range 2.22–3.88), protein 1.09 g/L
(normal range 0.15–0.40), and cryptococcal culture quantitative count
was 45 colony forming units (cfu)/mL.
CD4 count on day +1 was 243 cells/mm3, HIV viral load on day +2
was undetectable, syphilis RPR was negative, hepatitis B surface an-
tigen was negative, malaria rapid diagnostic test was negative, and
creatinine/potassium levels were normal.
Echocardiogram on day +1 revealed no clots or other
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abnormalities. Chest X-ray was normal. Computerised tomography and
magnetic resonance brain imaging were not available on site.
The patient received Ceftriaxone 2 g intravenously once daily to
treat bacterial meningitis. This was stopped on day +1 following po-
sitive CSF tests for cryptococcal meningitis. She was started on aspirin
75 mg orally once/day. Anti-retroviral treatment and co-trimoxazole
prophylaxis were continued. Two weeks of intravenous amphotericin B
(AmB) 1 mg/kg once/day was started on day +2. Two litres of in-
travenous normal saline with 20 mmol potassium chloride, 1200 mg
twice daily of oral potassium chloride, and three tablets once daily of
magnesium glycerophosphate were given on each day of AmB treat-
ment. Dexamethasone treatment (12 mg intravenously twice daily for 2
days) was given on days +3 and +4 to mature the foetal lungs, in view
of the chance of premature delivery. The patient received a unit of
blood on day +8 following a drop in haemoglobin from 9.1 g/dL on
day +1 to 7.0 g/dL on day +6 (haemoglobin normal range
11.8–14.8 g/dL).
Lumbar puncture was repeated on day +7, when the opening
pressure was 45 cm water, and the cryptococcal quantitative count was
30 cfu/mL. A ﬁnal lumbar puncture was performed on day +14 when
the opening pressure was 22, and the cryptococcal quantitative count
was 0 cfu/mL.
The patient improved with the two weeks of AmB treatment, and
oral ﬂuconazole 400 mg twice per day then started. The ﬂuconazole
dose was reduced to 400 mg orally once/day 2 weeks later. The patient
spontaneously entered labour 6 weeks following her presentation at 36
weeks gestation and delivered a healthy, but slightly underweight, baby
boy (weight = 1.8 kg) without any noticeable congenital abnormal-
ities.
An MRI Brain was performed after discharge (day +59) and is
displayed in Fig. 1. Brain imaging was not performed earlier due to the
clinical risk to the patient and her baby of problems arising during
transport to another hospital 1 hour away. Brain imaging was still
thought helpful to exclude diﬀerential diagnoses (e.g. brain abscess,
tuberculoma, toxoplasmosis, lymphoma etc).
The patient was reviewed in clinic on day +123. She had gradually
been improving at home, but severe neurological impairment persisted.
At review her right-sided hemiparesis remained evident with con-
tractures of the right foot and hand. She could walk with the assistance
of one person, was able to eat and drink herself, and was breastfeeding.
At this time she remained on ﬂuconazole 200 mg once daily, tenofovir/
lamivudine/efavirenz once daily, co-trimoxazole 960 mg once daily
and aspirin 75 mg once daily.
3. Discussion
Experience on the treatment of patients with cryptococcal me-
ningitis, disseminated cryptococcosis and pulmonary cryptococcosis in
pregnancy is limited to case reports and small series totaling 50 cases
(Table 1). There have been only 3 documented cases of mother-to-child
transmission of cryptococcus [4–6]. Three of the 8 (38%) cases reported
of cryptococcal meningitis in conﬁrmed HIV positive patients resulted
in maternal death (Table 1).
Pregnancy may well be a predisposing factor for the development of
cryptococcal disease [8]. Protection from cryptococcal disease is de-
pendent on a good Th1 weighted cell-mediated immune response. The
predisposition to cryptococcal disease in pregnancy likely relates to the
necessity for tolerance by the mother's adaptive immune system to
paternal antigens present in the foetus. CD4+ T-helper responses and
number are reduced during pregnancy, with the greatest suppression in
responses in the third trimester [9]. Additionally, in the context of
patients with HIV infection oﬀ antiretroviral treatment, pregnancy re-
versibly reduces CD4 counts [10]. It is also possible to demonstrate a
reduction in delayed hypersensitivity skin responses in pregnancy [7].
The weighting of T-cell responses in pregnancy changes from a Th1 cell-
mediated (IFN-γ, IL-12) to a Th2 (IL-4, IL-10) antibody-mediated and T-
regulatory (TGF-β) response [11]. The number of T-regulatory cells in
peripheral blood actually increases during early pregnancy, peaks
during the second trimester, and then declines post-partum [11]. Oes-
trogen reduces the activation of T-cells [12] and T-regulatory cell
numbers correlate with oestrogen levels [13]. Progesterone is also
considered to be immunosuppressive [14]. Progesterone has a positive
role in the production of the T-regulatory cytokine IL-10, can induce
Th2 weighted immune responses, reduce inﬂammatory cytokine pro-
duction, reduce Th1 weighted immune responses and suppress allo-
geneic responses [11]. Therefore pregnancy-related hormonal increases
in both progesterone and oestrogen appear immunosuppressive.
Table 1 demonstrates that symptoms of cryptococcosis began pre-
pregnancy in 2 cases (4%), during the ﬁrst trimester in 8 cases (16%),
the second trimester in 18 cases (36%), the third trimester in 18 cases
(36%) and post-partum in 4 cases (8%). Symptomatic presentation
therefore appears to be most common in the latter stages of pregnancy
in keeping with the increased immunosuppression at this time.
This patient presented with a left middle cerebral artery stroke.
Seventeen of 87 (20%) HIV positive cryptococcal meningitis patients
had cortical or lacunar infarction [2], and 7 of 37 (19%) of im-
munocompetent patients with cryptococcal meningitis had cerebral
infarction [15]. Therefore stroke is not an uncommon component of
cryptococcal meningitis presentation.
Options for the treatment of cryptococcal disease include
Amphotericin B based intravenous therapy, oral ﬂucytosine and oral
ﬂuconazole. The Infectious Diseases Society of America (IDSA) guide-
lines on the treatment of disseminated cryptococcal disease in preg-
nancy recommends AmB based therapy with or without ﬂucytosine
[16]. AmB is a category B pregnancy drug indicating that there is no
evidence of pregnancy risk in humans from its use following extensive
clinical use for both cryptococcosis and other infections [17]. Flucyto-
sine is a category C pregnancy drug indicating that not enough research
Fig. 1. MRI Brain Imaging of the patient at day +59.
T2-weighted images (A, B) and DWI image (C) de-
monstrate extensive hyperintensity in the left frontal,
parietal and temporal lobes, as well as the left cau-
date and lentiform nucleus, in keeping with a large
left middle cerebral artery territory infarct. There is
ventricular dilatation indicating hydrocephalus.
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has been done to determine if it is safe. Flucytosine crosses the placenta
and animal studies have shown the potential for teratogenicity at doses
lower than the human dose [17]. However, ﬂucytosine has been used in
three cases of cryptococcal disease in the later stages of pregnancy
without adverse eﬀects on the fetus [17]. There is no information to
guide the safety of ﬂucytosine whilst breastfeeding although the man-
ufacturer advises avoidance.
Fluconazole treatment of more than a single 150 mg dose is a ca-
tegory D pregnancy drug indicating that there is positive evidence of
human fetal risk. Fluconazole is a triazole which selectively inhibits
fungal cytochrome P-450 preventing the fungus from building its cell
wall [18]. It is potentially teratogenic, and results in a characteristic
pattern of malformations [18]. It seems that a relatively high dose (over
400 mg) is required, and that the critical period of exposure is likely to
be the ﬁrst half of pregnancy [18]. Fluconazole is secreted in breast
milk but is considered safe in children [19]. The IDSA guidelines [16]
recommend avoiding ﬂuconazole in the ﬁrst trimester, judging the use
of ﬂuconazole in the second and third trimester according to need, and
starting ﬂuconazole after delivery. Ely and colleagues suggest 4–6
weeks of treatment with intravenous AmB with co-administration of
oral ﬂucytosine, followed by oral ﬂuconazole after delivery [7].
This case highlights the diﬃculties in diagnosing and treating
cryptococcal disease in pregnancy. The presentation of cryptococcal
meningitis in pregnancy with a stroke in the absence of headache, in the
context of well-controlled HIV, an unexpectedly high CD4 count (243
cells/mm3) and low cryptococcal CSF count (45 cfu/mL) is unusual. It is
likely that the immunosuppression of pregnancy contributed to the
development of this opportunistic infection. We would advocate the
initial use of AmB in the treatment of similar patients, with or without a
1–2 week course of ﬂucytosine. Results from the recent ACTA trial
suggest one week of AmB plus ﬂucytosine provides eﬀective induction
with fewer side eﬀects than 2 weeks [20], but special circumstances
such as this case, duration of induction could also be guided by culture
results. If it is decided to avoid ﬂuconazole, especially early in preg-
nancy, further alternate day and/or intermittent dosing of AmB could
provide consolidation and maintenance while minimising side eﬀects.
Table 1
50 published cases of cryptococcal disease in pregnancy.
Author Year HIV status Cryptococcal diagnosis Gestation at disease onset (trimester) Outcome mother Outcome baby
Timerman 1935 Not speciﬁed CM 3rd Died Died
Wager 1954 Not speciﬁed CM 3rd Died Survived
Gantz 1958 Not speciﬁed CM Postpartum Died Survived
Feldman 1959 Not speciﬁed CM 2nd Survived Survived
Littman 1959 Not speciﬁed CM 2nd Survived Not speciﬁed
Aitken 1962 Not speciﬁed CM 1st Survived Survived
Kuo 1962 Not speciﬁed CM 3rd Survived Survived
Crotty 1965 Not speciﬁed CM 1st Died Not speciﬁed
Crotty 1965 Not speciﬁed CM 2nd Died Not speciﬁed
Crotty 1965 Not speciﬁed CM 3rd Died Not speciﬁed
Crotty 1965 Not speciﬁed CM + PC Postpartum Died Not speciﬁed
Philpot 1972 Not speciﬁed CM 1st Died Died
Philpot 1972 Not speciﬁed CM + PC 1st Survived Survived
Silberfarb 1972 Not speciﬁed CM Postpartum Survived Survived
Curole 1981 Not speciﬁed CM 1st Survived Survived
Curole 1981 Not speciﬁed CM 2nd Survived Survived
Jones 1983 Not speciﬁed CM 3rd Survived Survived
Staﬀord 1983 Not speciﬁed CM 2nd Not speciﬁed Not speciﬁed
Chotmongkol 1991 Not speciﬁed CM Pre Pregnancy Survived Survived
Chotmongkol 1992 Not speciﬁed CM 1st Not speciﬁed Not speciﬁed
Pereira 1993 Not speciﬁed CM 1st Survived Survived
Pereira 1993 Not speciﬁed CM 2nd Survived Survived
Chen 1996 Not speciﬁed CM 3rd Survived Survived
Ely [7] 1998 Not speciﬁed CM 3rd Survived Survived
Ely [7] 1998 Not speciﬁed PC Pre-pregnancy Survived Survived
Ely [7] 1998 Not speciﬁed PC 3rd Survived Survived
Nakamura 2009 Not speciﬁed PC 3rd Survived Survived
Nakamura 2009 Not speciﬁed CM + PC 3rd Survived Survived
Molnar-Nadasdy 1994 Negative CM 2nd Survived Died
Ely [7] 1998 Negative PC 3rd Survived Survived
Ely [7] 1998 Negative PC 2nd Survived Survived
LaGatta 1998 Negative PC Postpartum Survived Survived
Nucci 1999 Negative CM 2nd Died Died
Vawda 2008 Negative PC 2nd Survived Survived
Costa 2009 Negative CM 1st Survived Survived
Mudumbi 2010 Negative PC + DC 2nd Survived Died
Pastagia 2010 Negative PC + DC 2nd Survived Died
Lachhab 2012 Negative CM 3rd Survived Survived
Chopra [8] 2015 Negative PC 2nd Survived Died
Chopra [8] 2015 Negative PC + CM 3rd Survived Survived
Nath 2016 Negative CM 2nd Not known Not known
Kida 1989 Positive DC 3rd Died Survived
Sirinavin [5] 2004 Positive CM 3rd Died Survived
Castro 2006 Positive CM 2nd Died Died
Darko 2011 Positive CM 2nd Survived Survived
Nayak 2011 Positive CM 2nd Survived Survived
Patel 2012 Positive CM 2nd Survived Survived
Kiggundu [6] 2014 Positive CM 3rd Died Survived
Ngwenya 2016 Positive CM 3rd Survived Survived
This report 2017 Positive CM 3rd Survived Survived
CM = Cryptococcal Meningitis, DC = Disseminated Cryptococcosis, PC = Pulmonary Cryptococcosis. See Supplementary appendix for non-numbered references.
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However, in the developing world setting of this case AmB, ﬂucytosine,
and CSF culture are often unavailable. The use of maintenance ﬂuco-
nazole may be reasonable in the second half of pregnancy, and ﬂuco-
nazole treatment should be instituted following delivery of the baby.
We would also advocate a low threshold for as required therapeutic
lumbar punctures as part of the treatment for cryptococcal meningitis.
Acknowledgements
The authors would like to thank the ACTA study for donating the
treatment medications, and for providing advice and support in
managing this patient. No funding for this case.
Conﬂict of interest statement
PDB: No conﬂicts of interest.
DL: No conﬂicts of interest.
JJvO: No conﬂicts of interest.
AChen: No conﬂicts of interest.
TSH: No conﬂicts of interest.
AChan: No conﬂicts of interest.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.mmcr.2017.10.002.
References
[1] B.J. Park, K.A. Wannemuehler, B.J. Marston, N. Govender, P.G. Pappas,
T.M. Chiller, Estimation of the current global burden of cryptococcal meningitis
among persons living with HIV/AIDS, AIDS 23 (4) (2009) 525–530.
[2] A. Loyse, A. Moodley, P. Rich, S.F. Molloy, T. Bicanic, L. Bishop, et al., Neurological,
visual, and MRI brain scan ﬁndings in 87 South African patients with HIV-asso-
ciated cryptococcal meningoencephalitis, J. Infect. 70 (6) (2015) 668–675.
[3] J.A. Veltman, C.C. Bristow, J.D. Klausner, Meningitis in HIV-positive patients in
sub-Saharan Africa: a review, J. Int. AIDS Soc. 17 (2014) 19184.
[4] E.B.D. Neuhauser, A. Tucker, The roentgen changes produced by diﬀuse torulosis in
the newborn, Am. J. Roentgenol. Radium Ther. 59 (6) (1948) 805–815.
[5] S. Sirinavin, U. Intusoma, S. Tuntirungsee, Mother-to-child transmission of
cryptococcus neoformans, Pediatr. Infect. Dis. J. 23 (3) (2004) 278–279.
[6] R. Kiggundu, J. Rhein, D.B. Meya, D.R. Boulware, N.C. Bahr, Unmasking crypto-
coccal meningitis immune reconstitution inﬂammatory syndrome in pregnancy
induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation,
Med. Mycol. Case Rep. 5 (2014) 16–19.
[7] E.W. Ely, J.E. Peacock, E.F. Haponik, R.G. Washburn, Cryptococcal pneumonia
complicating pregnancy, Medicine 77 (3) (1998) 153–167.
[8] S. Chopra, M.R. Capoor, R. Mallik, S. Gupta, A. Ray, G. Khanna, et al., Pulmonary
Cryptococcosis in HIV sero-negative patients: case series from India, Mycoses 58 (5)
(2015) 288–293.
[9] F. Sabahi, M. Rola-Plesczcynski, S. O’Connell, L.D. Frenkel, Qualitative and quan-
titative analysis of T lymphocytes during normal human pregnancy, Am. J. Reprod.
Immunol. 33 (5) (1995) 381–393.
[10] R. Heﬀron, D. Donnell, J. Kiarie, H. Rees, K. Ngure, N. Mugo, et al., A prospective
study of the eﬀect of pregnancy on CD4 counts and plasma HIV-1 RNA con-
centrations of antiretroviral-naive HIV-1–infected women, J. Acquir. Immune Deﬁc.
Syndr. 65 (2) (2014) 231–236.
[11] D. Song, Y. Shi, Immune system modiﬁcations and feto-maternal immune tolerance,
Chin. Med. J. 127 (17) (2014) 3171–3180.
[12] S.E. Segerer, N. Müller, J. van den Brandt, M. Kapp, J. Dietl, H.M. Reichardt, et al.,
Impact of female sex hormones on the maturation and function of human dendritic
cells, Am. J. Reprod. Immunol. 62 (3) (2009) 165–173.
[13] L. Arruvito, M. Sanz, A.H. Banham, L. Fainboim, Expansion of CD4+CD25+ and
FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: im-
plications for human reproduction, J. Immunol. 178 (4) (2007) 2572–2578.
[14] T. Adar, S. Grisaru-Granovsky, A. Ben Ya’acov, E. Goldin, A. Bar-Gil Shitrit,
Pregnancy and the immune system: general overview and the gastroenterological
perspective, Dig. Dis. Sci. 60 (9) (2015) 2581–2589.
[15] S.-F. Chen, C.-H. Lu, C.-C. Lui, C.-R. Huang, Y.-C. Chuang, T.-Y. Tan, et al., Acute/
subacute cerebral infarction (ASCI) in HIV-negative adults with cryptococcal me-
ningoencephalitis (CM): a MRI-based follow-up study and a clinical comparison to
HIV-negative CM adults without ASCI, BMC Neurol. BioMed. Cent. 11 (2011) 12.
[16] J.R. Perfect, W.E. Dismukes, F. Dromer, D.L. Goldman, J.R. Graybill, R.J. Hamill,
et al., Clinical practice guidelines for the management of cryptococcal disease: 2010
update by the infectious diseases society of America, Clin. Infect. Dis. 50 (3) (2010)
291–322.
[17] C.T. King, P.D. Rogers, J.D. Cleary, S.W. Chapman, Antifungal therapy during
pregnancy, Clin. Infect. Dis. 27 (5) (1998) 1151–1160.
[18] E. Lopez-Rangel, M.I. Van Allen, Prenatal exposure to ﬂuconazole: an identiﬁable
dysmorphic phenotype, Birth Defects Res. A Clin. Mol. Teratol. 73 (11) (2005)
919–923.
[19] Y.C. Kaplan, G. Koren, S. Ito, P. Bozzo, Fluconazole use during breastfeeding, Can.
Fam. Physician 61 (10) (2015) 875–876.
[20] S. Molloy, C. Kanyama, R. Heyderman, A. Loyse, C. Kouanfack, D. Chanda, et al., A
randomized controlled trial for the treatment of HIV-associated cryptococcal me-
ningitis in Africa: oral ﬂuconazole plus ﬂucytosine or one week amphotericin-based
therapy vs two weeks amphotericin-based therapy, The ACTA Trial, Oral
Presentation. International AIDS Society, 2017.
P.D. Bright et al. Medical Mycology Case Reports 19 (2018) 9–12
12
